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Abstract: Frutalin is a plant lectin with beneficial immunobiological action, although the access to its
active form is still restricted. Moreover, there is a knowledge gap on isoform activity and glycosylation
impact on its bioactivity, and recombinant production protocols were seen as ineffective. Here, a
simpler and faster production and purification protocol was developed, attaining a yield of purified
frutalin 3.3-fold higher than that obtained previously. Hemagglutination assays confirmed that this
frutalin isoform could not agglutinate rabbit erythrocytes, while maintaining the native tetrameric
structure, as indicated by DLS analysis, and strong interaction with methyl-alpha-galactose, in
fluorescence spectroscopy studies. The cytotoxicity of the recombinant frutalin isoform was shown in
a broad panel of human cancer cells: colon (HCT116), melanoma (A375), triple-negative breast cancer
(MDA-MB-231), and ovarian (IGROV-1). Treatment with 8.5–11.8 µM TrxFTL reduced proliferation
of all cancer cells to half in 48 h. This anti-proliferative effect encompasses the p53 pathway since
it was significantly reduced in p53-null colon cancer cells (HCT116 p53−/−; GI50 of 25.0 ± 3.0 µM),
when compared to the isogenic p53-positive cells (HCT116 p53+/+; GI50 of 8.7 ± 1.8 µM; p < 0.002).
This recombinantly produced frutalin isoform has relevant cytotoxic effect and its biological activity
is not dependent on glycosylation. The developed E. coli production and purification protocol
generates high yield of non-glycosylated frutalin isoform with potent cytotoxic activity, enabling the
development of novel anticancer p53-targeting therapies.
Keywords: recombinant frutalin; isoforms; Escherichia coli; targeted anticancer therapy; p53
1. Introduction
Frutalin lectin has been extensively studied in recent years, mainly in immunobi-
ological research, due to its outstanding biological properties. These include, for ex-
ample, gastroprotection [1], tissue repair, regeneration and chronic wound healing [2],
antidepressant-like effect [3], and antitumor activity, resulting from the recognition of
cancer-associated oligosaccharides [4]. As other lectins, frutalin isolated from its natural
source (breadfruit seeds) is a mixture of isoforms [5]. Slight (but important) differences
in amino acids sequences (from 3 to 7%) were identified in frutalin isoforms [6]. Such
differences also account for a partial glycosylation in final samples. It is well-known
that each lectin isoform can interact differently with cells, leading to distinct cytoaggluti-
natination and cytotoxic activities [5]. It is still unclear the role of glycosylation on such
biological diversity, while it seems a critical factor on lectins stability [7]. Sample hetero-
geneity, together with geographical and seasonal source-dependence, and low purification
yield, restricts further exploitation of the biomedical properties of frutalin. The bacteria
Escherichia coli was tested as recombinant host by employing direct cDNA cloning and no
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fusion partners, but the production yield of soluble frutalin was low [6]. Still, recombinant
frutalin revealed agglutination properties and carbohydrate-binding specificity similar to
the native lectin [6]. On the other hand, the yeast Pichia pastoris has proven to be an effective
alternative to obtain soluble, stable, and functional frutalin samples [8]. Interestingly, while
native frutalin demonstrated a strong hemagglutinating activity, the recombinant frutalin
did not present such capacity, which could either be due to hampering effects of yeast
glycosylation or to an intrinsic characteristic of the cloned isoform [8]. Still, recombinant
frutalin showed irreversible antiproliferative effect on HeLa cervical cancer cells, as native
frutalin, and higher specificity as a biomarker of human prostate cancer [4,9]. Nonetheless,
the production and purification process of frutalin in yeast was relatively slow, laborious,
and resulted in modest yields [8].
With the great advances in fusion tag technology, for enhancing protein productivity
and solubility, mainly in E. coli, several difficult-to-express proteins can now be produced
in this host at reasonable yields [10–13]. As such, the aim of this study was to develop
a novel strategy to produce and purify higher amounts of biologically active frutalin
in E. coli, based on previously reported guidelines [11–14], and to study its antitumor
activity. The molecular cloning approach employed in this work consisted in codon bias
optimization, fusion with a solubility enhancer (TrxA) and a purification tag (6xHistag),
followed by optimization of the culture conditions, and partners’ cleavage. The target
frutalin isoform was the one previously produced in P. pastoris [8]. Biological activity of the
non-glycosylated frutalin obtained in E. coli was studied in vitro with rabbit erythrocytes
and human cancer cells to ascertain its functionality and elucidate glycosylation importance
on cells recognition. In addition, taking advantage of the improved production and
purification of this recombinant frutalin isoform, its effect on different human cancer cell
lines was for the first time evaluated.
2. Results
2.1. Expression and Purification of Recombinant Frutalin
Previously, the frutalin isoform of this work was successfully produced in P. pastoris
by a 5-days induction process and purified by size exclusion chromatography (SEC) [8].
However, SEC led to a large dilution of recombinant frutalin during separation, while
a concentration step was required for downstream applications. Hence, production of
frutalin in yeast was found to be a time-consuming process of moderate yield (up to
20 milligrams per liter of culture), whilst the pure product consisted in a mixture of
glycosylated and non-glycosylated forms [8]. Then, E. coli was employed as alternative
host, but resulted in low soluble amounts of protein, despite optimization of codon usage
and induction conditions (inducer concentration, temperature, and time of induction)
(unpublished results). Furthermore, purification of soluble protein fraction by IMAC
was very inefficient. Similar failure was found in the purification of frutalin produced
in P. pastoris also by IMAC (unpublished results). The difficulty in purifying frutalin in
these works using the small 6xHistag placed directly at its N-terminal or C-terminal, in
bacteria and yeast, respectively, can be attributed to the location of these ends in the 3D
frutalin structure, which according to the built model, are hidden (Figure 1). As it can be
observed in the model, the C-terminal of α chains (silver) and the N-terminal of β-chains
(yellow) are placed inside the frutalin tetrameric structure (Figure 1), which presents the
typical symmetric β-prism fold of jacalin-related lectins [15]. Importantly, in contrast to
native frutalin, the first amino acid in α chain (Gly25) is not free in recombinant frutalin,
but it is connected to β chain by the linker TSSN (in red; Figure 1), being a key factor in the
structural arrangement of the residues involved in the sugar-binding site of D-galactose
(Gly25, Tyr146, Trp147, and Asp149) [15]. Not relevant for the model, but determinant for
purification, the 6xHistag was placed at the N-terminal of frutalin (β chain) via connection
of 13 extra amino acids (which includes the TEV recognition site) (Table 1). These amino
acids functioned as a spacing linker that improved the availability of 6xHistag to interact
with the Ni2+ resin [11], thus enabling the efficiency of frutalin purification by IMAC.
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Later, in a comparative tags study, the soluble production of another frutalin isoform 
was considerably improved by using different solubility enhancers, such as the TrxA, and 
the 6xHistag for purification by IMAC, being the protein soluble after partners’ removal 
by TEV cleavage (Tobacco Etch Virus protease) [14]. Thus, a similar strategy was followed 
Figure 1. Putative molecular model of recombinant frutalin. The β chains are colored in yellow and
the α chains in silver in tetrameric structure. The four amino acid linker TSSN, which binds α and β
chains, is represented in red. The carbohydrate-binding site involves the N-terminus of the α chain
and is formed by four key residues: Gly25, Tyr146, Trp147, and Asp149 [15]. Alterations in the spatial
position of Trp residues upon frutalin binding to carbohydrates, principally in α chain, contribute to
intrinsic fluorescence changes. The Trp residues are represented in green and magenta in α and β
chains, respectively.
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Later, in a comparative tags study, the soluble production of another frutalin isoform
was considerably improved by using different solubility enhancers, such as the TrxA, and
the 6xHistag for purification by IMAC, being the protein soluble after partners’ removal by
TEV cleavage (Tobacco Etch Virus protease) [14]. Thus, a similar strategy was followed with
the isoform selected for this work. Indeed, frutalin was produced in soluble form from E.
coli BL21 in fusion with TrxA (TrxFTL) at high amounts. The fusion protein strategy boosted
the availability of FTL by increasing its yield from few micrograms to dozens of milligrams
per liter of E. coli culture, whilst simplifying the whole production and purification protocol.
Roughly, 18 mg of purified TrxFTL per gram of fresh biomass was obtained. IMAC revealed
to be a simpler, easier, and quicker procedure than SEC for frutalin purification. Purified
TrxFTL migrated in SDS-PAGE (Figure 2), as a homogeneous single band with a molecular
weight close to its calculated molecular weight (MW) (~32 kDa; Table 1). Purified cFTL
could be observed in gel as a single band of ~17 kDa (Figure 2), which is also consistent
with the predicted MW of the cloned frutalin sequence (Table 1). The same pattern in
SDS-PAGE gel was also obtained by other frutalin isoform produced and purified in E. coli;
however, at the µg per liter scale [6]. Thus, it can be concluded that fusion tag technology,
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together with optimization of codon usage and production and purification process, was
essential for obtaining high pure yield of the difficult-to-express frutalin isoform.
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Frutalin is a tetrameric protein in nature [8,16]. If the recombinant frutalin obtained
from E. coli acquires a tetrameric structure, the expected theoretical MW of TrxFTL would
be 126 kDa (monomer with 31.6 kDa; Table 1) and the theoretical MW of cleaved FTL from
TrxFTL would be 70 kDa (monomer with 17.4 kDa; Table 1). According to calculations of
DLS software, apparent diameter of TrxFTL should be higher than that of cFTL, namely:
9.4 nm (4.7 nm of apparent radius) for TrxFTL and 7.3 nm (3.7 nm of apparent radius)
for cFTL. These theoretical measurements are in complete agreement with what can be
observed in Figure 3, where the population of TrxFTL and cFTL presents a diameter close
to 7.5 nm and 9.5 nm, respectively. Thus, DLS not only suggests tetrameric forms, for either
TrxFTL or cFTL, but also that cFTL was perfectly cleaved form TrxFTL. Finally, TrxFTL
appears to be highly homogenous, while cFTL seems to have some heterogeneity, due to
the presence of high MW aggregates, as indicated by the presence of populations with high
diameters (Figure 3A). The high homogeneity in TrxFTL samples enabled its purification
without a SEC refining step.
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Figure 3. Size distribution by intensity for TrxFTL (red line) and FTL cleaved from TrxFTL (green
line). (A) Size scale 0.01–10,000 nm diameter; (B) size scale 1–50 nm diameter. Estimated diameter for
TrxFTL (9.4 nm) is higher than that estimated for cFTL (7.3 nm). Each curve represents the average of
10 independent measurements.
2.3. Hemagglutinating Activity
ative frutalin is known by its strong hemagglutinating activity towards rabbit ery-
throcytes [8]. Contrarily to native frutalin, no visible hemagglutinating activity was de-
tected in these cells with purified TrxFTL or cFTL (Figure 4). A lectin obtained by recombi-
nant mea s can lack hemagglutinating activity for basically three reasons: the lectin does
not adopt the correct ligomeric conformati n (hemagglutination activity presupposes at
lea t two binding sites, e.g., by dimer formation); glycosylation, or other post-translational
modification, in case of a lectin pr duc d from a eukaryotic organism, exerts structural
effects that can hamper this activity; and the clo ed gene corresponds to a isoform that
d es not have this acti ity (many lectins re a mixture of isoforms with few amino acids
differences, enough for giving them d fferent biological activities). Prev ously, it was
hypothesized that glycosyla ion might inhibit hemagglut nating activity of frutalin. How-
ever, the same frutalin version (same amin acids s quence) produced i a deglycosylated
form in E. coli (this work) and in a partly-glycosylated form in P. past is (possibly, at
Asn74) [8] did not present this activity, while nother isoform wit 92% of sequence iden-
tity obtained in E. coli was able to agglutinate rabbit erythrocytes [6]. Structural studies
indicated t trameric structure for all frutalin versions, including TrxFTL (this work). T e
isoform having agglutination capacity, while being non-glycosylated, differs in 12 amino
acids in a total of 157 [6]. Thus, it can be assumed that the absence of hemagglutinatin
capacity in frutalin is dependent on the isoform (amino acid sequence), and not on the
glycosylation. It is now clear that frutalin isoforms have different biological activities,
regardless the presence or absence of glycosylation. Interestingly, the same conclusion
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about glycosylation was recently taken in the case of other lectins [7,17]. For example,
the role of glycosylation of Curcuma longa rhizome lectin was studied by structural and
activity assays conducted with wild-type lectin, deglycosylated form produced in E. coli,
glycosylated form produced in P. pastoris, and glycosylated mutants N66Q and N110Q,
also produced in P. pastoris. Circular dichroism, fluorescence spectroscopy, and hemagglu-
tinating studies showed no differences in secondary or tertiary structures, or sugar binding
properties, between native lectin and each recombinant lectin form under physiological
pH [7]. Although glycosylation was found important to maintain correct lectin folding at
acidic pH [7].
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Similarly, a large increase (~46%) in the maximum fluorescence emission of TrxFTL was 
observed in the presence of methyl-α-galactose (Figure 5). This result confirms that 
TrxFTL also binds to this sugar. No interaction with D-galactose was detected. Most prob-
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(alpha- and beta-chain) that comprise the lectin [8,18]. Peptide excision presumably re-
duces the rigidity of frutalin carbohydrate-binding site, increasing the number of interac-
tions with ligands and resulting in multiple-binding sites and anomeric recognition of α-
D-galactose sugar moieties [15]. Nevertheless, the loss in sugar binding affinity did not
compromise the ability of jacalin or frutalin to recognize cancer cells [4,9,19].
Figure 4. Photos of hemagglutinating assays carried out in 1.5 mL Eppendorfs with native
frutalin (A), TrxFTL (B), and cFTL (C) for the higher concentration tested (0.2 mg/mL). A coag-
ulum at the bottom of the Eppendorf is clearly visible in the presence of native frutalin (A), but not in
the presence of TrxFTL (B) and cFTL (C).
2.4. Interaction with Methyl-α-Galactose
The fluorescence emission spectrum of TrxFTL showed an emission maximum at
328 nm. The same isoform produced in P. pastoris presented a fluorescence emission
maximum at 333 nm [8]. Among many sugars studied, the recombinant frutalin produced
in yeast demonstrated preference for ethyl-α-galactose, hich led to high enhancements
in frutalin fluorescence emission (~35%) [8]. Thus, the response of fluorescence emission
of TrxFTL in presence of this sugar, at the same concentration (100 mM), was analyzed.
Similarly, a large increase (~46%) in the maximum fluorescence emission of TrxFTL was
observed in the presence of methyl-α-galactose (Figure 5). This result confirms that TrxFTL
also binds t this ugar. No interaction with D-galactose was detected. Most probably,
TrxFTL has identical sugar affinity to recombinant frutali produced in yeast. According to
previous studi s, recombinant frutalin and jacalin pro uced i E. coli presented a ~100-fold
lower affinity for methyl-α-galac ose (associa ion constan s i the order of 102 M−1) than
the corresponding native lectins (asso iation constants in the order of 104 M−1). This is
due to the absenc of a proteolytic event in the recombinant host related to the cleavage
of the four amino acid peptide “T-S-S-N”, which conne ts the two polypeptides (alpha-
and beta-chain) that comprise the lectin [8,18]. Peptide excision presumably reduces th
rigidity of frutalin carbohydrate- inding site, increa ing the number of interacti ns with
liga ds and resulting in multiple-binding sites and anomeric recognition of α-D-galactose
sugar moieties [15]. Nevertheless, the loss in sugar bindi g affinity did not compromise
the ability of jacalin or frutalin to recognize cancer cells [4,9,19].
Molecules 2021, 26, 4712 7 of 13




Figure 5. Fluorescence emission spectra of TrxFTL in the absence (solid line) and presence (dashed 
line) of methyl-α-galactose in PBS. 
2.5. Antitumor Activity 
The growth inhibitory effect of TrxFTL and cFTL was initially compared in the hu-
man cancer cell line HCT116 p53+/+. An identical dose-response curve was obtained for the 
two recombinant forms, showing once more that the TrxA tag does not interfere with fru-
talin activity, in agreement with the DLS and hemagglutination assays. Then, TrxFTL was 
further evaluated in a panel of distinct human cancer cell lines of colon (HCT116 p53+/+ 
and HCT116 p53−/−), melanoma (A375), triple-negative breast cancer (MDA-MB-231), and 
ovarian (IGROV-1), using the SRB assay. A dose-response curve was obtained for TrxFTL 
in the distinct cancer cells and the GI50 was determined after 48 h treatment (Table 2; Figure 
6). TrxFTL inhibited the growth of HCT116, A375, IGROV-1, and MDA-MB-231 cells. In-
terestingly, this anti-proliferative effect of TrxFTL revealed to involve the p53 pathway 
since it was significantly reduced in p53-null HCT116 cells (HCT116 p53−/−), when com-
pared to the isogenic HCT116 p53+/+ cells (Table 2). It should also be noted that the effec-
tiveness of TrxFTL on MDA-MB-231 cells, expressing mutant p53, might indicate its abil-
ity to target both wild type and mutant p53 forms. In the non-tumor colon cancer cell line 
CCD-18Co, the GI50 value was approximately 2-fold higher than that obtained in the 
HCT116 p53+/+ (16.5 ± 2.2 μM, n = 4 independent experiments), which revealed some se-
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Table 2. Effect of frutalin produced in E. coli in fusion with TrxA (TrxFTL) on the growth of different
human cancer cell lines and effect of frutalin produced in P. pastoris on the growth of HCT116 p53+/+
cell line (control).
Frutalin Version Cancer Cell Lines GI50 (µM)
Frutalin produced in P. pastoris HCT116 p53+/+ 8.5 ± 0.6
Frutalin produced in E. coli in fusion
with TrxA (TrxFTL)
HCT116 p53+/+ 8.7 ± 2.6
HCT116 p53−/− 25.0 ± 3.0 **
A375 8.5 ± 0.8
IGROV-1 10.3 ± 0.7
MDA-MB-231 11.8 ± 1.1
GI50 values were determined by SRB assay after 48 h treatment (growth obtained with vehicle was set as
100%). Data are shown as mean ± SE of four to six independent experiments; values of HCT116 p53−/− cells
significantly different from HCT116 p53+/+ cells are indicated (** p = 0.002, unpaired Student’s t-test).
3. Discussion
In this work, a frutalin isoform with anticancer activity was produced in E. coli in
fusion with TrxA, for enhancing its solubility and yield, and His6, for facilitating its
purification. TrxFTL appeared in SDS-PAGE gel as a single band of ~32 kDa, whereas
cleaved FTL migrated gel as a single band of ~17 kDa (Figure 1), which is in complete
agreement with MW of previous recomb nant frutalin either expressed in bacteria or
yeast hosts [6,8]. As expected, a good yield of purified protein was obtain , 66 mg of
protei p r liter of culture, which was exceptionally higher (868-fold incr ase) than t e
first yield obtained in E. coli, 76 µg of pure frutalin per liter of E. coli culture [6]. When a
microbial host of higher production capacity was employed, P. pastoris, the same frutalin
isoform could be obtained at the maximum of 20 mg per liter of culture [8]. This means
that a 3.3-fold improvement in frutalin yield was achieved in this work. Furthermore,
the production and purification protocols were much si plified: shake-flask production
was reduced from 5-days to 1-day, and purification, although still consisting in two steps
(affinity chromatography plus buffer exchange), was faster and less prone to losses than
previous method (size-exclusion chromatography plus concentration by ultrafiltration) [8].
However, one limitation of using the E. coli expression system could have been the lack
of proper glycosylation, since frutalin is a partly glycosylated lectin in nature. For this
reason, the biological activity of TrxFTL was investigated in detail. Unlike other frutalin
isoform [6], and native frutalin [18], TrxFTL and cFTL did not present hemagglutinating
activity (Figure 4). This result cannot be attributed to conformation issues since the native
tetrameric frutalin structure was suggested to be present in TrxFTL and cFTL by DLS
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analysis (Figure 3). This result explains that the lack of hemagglutination activity in the
same tetrameric isoform obtained in yeast is not due to Pichia glycosylation pattern. Then,
it can be concluded that different frutalin isoforms have different biological activities, as
reported for other lectins that are also comprised by a mixture of isoforms [5]. Other
observations indicated that the activity of frutalin recombinantly obtained in bacteria is
identical to the one obtained in Pichia. TrxFTL strongly interacted with methyl-α-galactose
(Figure 5), but not with galactose, like frutalin recombinantly produced in yeast [8]. In
addition, it showed antiproliferative activity against cancer cells, either in fusion or cleaved
from partners. Results of TrxFTL in HCT116+/+ cells are quite close to results obtained with
same frutalin isoform produced in P. pastoris, which showed a GI50 of 8.5± 0.6 µM (Table 2).
Frutalin obtained in yeast also presented a dose-dependent cytotoxicity on human cervical
cancer cells, HeLa cells (GI50 ~6 µM), whose results were in accordance with native frutalin
effects [4]. Since the two frutalin versions of same isoform, partly glycosylated [8] and
non-glycosylated (this work), have identical magnitude of cytotoxicity on human cancer
cells, it can be concluded that glycosylation is not involved on this activity. This work is in
line with other studies reporting that the biological activities of lectins are independent of
glycosylation [5,7,20]. This work also shows, for the first time, the cytotoxic effect of frutalin
on melanoma, ovarian and triple-negative breast cancer cell lines, which further reinforces
the great potential of recombinant frutalin as an anti-cancer drug (Table 2; Figure 6).
The cytotoxicity of plant lectins has been extensively studied on a diversity of can-
cer cell lines (for a revision, see e.g., Table 3 in [21]). For example, very recently, the
antiproliferative activity of the galactose-binding plant lectin BfL-II, produced and purified
from E. coli, was evaluated in human breast (MCF-7) and colorectal (HT-29) cancer cells,
showing to be stronger on colorectal cancer cells, while at much higher concentration than
frutalin [20]. Plant lectins exert their antiproliferative activity by inducing programmed
cell death pathways (apoptosis and/or autophagy). Frutalin has been shown to induce cell
death on HeLa cells by apoptosis [4]. The possible molecular mechanism by which plant
lectins induce tumor cell death by apoptosis involves, at first place, the lectin interaction
with sugar binding receptors present on the plasma membrane, followed by internalization
through endocytosis [22]. This event has been previously observed in the interaction of
frutalin produced in P. pastoris, and native frutalin, with HeLa cells [4]. Rapidly (within 1-h
incubation), both frutalin versions were completely internalized and detected around and
inside HeLa nucleus [4]. Sugar binding receptors of jacalin-related lectins, to which family
frutalin belongs, are mostly Tn, sTn, and T antigens [21]. These abnormal O-glycans are
expressed on several types of cancer, including colon or breast cancers, and are associated
with adverse outcomes and poor prognosis [23]. The structure of many lectins, including
jacalin, in complex with T antigens have been previously revealed [24]. Interestingly, strong
interaction of native frutalin with T antigen (Galb(1-3)GalNac) was observed in our pre-
vious work, but no interaction with this sugar could be detected for frutalin produced in
yeast [8]. This result suggests the presence of other frutalin receptors, such as methylated
glycans, rather than T antigens. Once inside the cells, the lectins can trigger an apoptotic
cell death mostly through a mitochondria-mediated pathway, involving relevant players
such as p53 [22]. Accordingly, activation of the p53 pathway has already been reported for
certain plant lectins. For example, recently, the bean lectin TBLF has shown to induce apop-
tosis in colon cancer cells by p-p53(ser46) involvement [25]. Nevertheless, no involvement
of jacalin-related lectins with p53 pathway has been described so far. Our work adds a
novel and important clue on the mechanism underlying frutalin-induced cancer cell death.
In fact, the results herein obtained indicate a potential involvement of the p53 pathway
in the antiproliferative activity of TrxFTL. Therefore, in a future work, it would be very
interesting to deeply elucidate this potential p53-dependent antitumor activity of frutalin.
In conclusion, fusion tag technology was effective in improving frutalin yield in E. coli,
not interfering with frutalin bioactivity. Moreover, frutalin was obtained in this host as an
active anticancer molecule of broad spectrum, which deserves to be further explored based
on its great potential in targeted anticancer therapy.
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4. Materials and Methods
4.1. Construction of Expression Vector
Frutalin mature sequence [8], with codons optimized for recombinant expression
in E. coli, flanked by NcoI and XhoI recognition sites at the 5′- and 3′-end, respectively,
was synthesized by NZYTech. The frutalin synthetic gene was excised from the carrying
plasmid by digestion with NcoI and XhoI enzymes and ligated to the pETM20 vector (EMBL)
in fusion with the N-terminal thioredoxin A (TrxA) and His6 tags (linked to the cloning
site by a TEV protease recognition sequence) [14]. The construct was transformed and
propagated in chemically competent NZY5a E. coli cells (NZYTech). For protein expression,
the construct was transformed into the E. coli strain NZYBL21 (DE3) (NZYTech).
4.2. Recombinant Protein Production and Purification
E. coli BL21(DE3) cells harboring the recombinant plasmid were grown overnight
at 37 °C in 10 mL LB medium containing 100 µg/mL of ampicillin. In the day after,
4 × 250 mL of same medium were inoculated with previous culture (1:1000) and grown to
an OD600 nm of 0.5 and recombinant protein expression induced with 0.2 mM IPTG for
16 h at 18 °C. Cells were recovered by centrifugation (at 4 °C for 15 min at 10,000 rpm) and
lysed with NZY Bacterial Cell Lysis Buffer (NZYTech) supplemented with 1 mM PMSF,
according to the manufacturer’s instructions. Soluble cell-free extracts were collected by
centrifugation, filtered (0.45 µM pore size), and loaded on a 5 mL Nickel HisTrap column
(GE Healthcare) for recombinant protein purification by immobilized metal ion affinity
chromatography (IMAC). Purification was conducted according to the manufacturer’s
instructions, using 50 mM Tris pH 8.0, 150 mM NaCl with 20 or 40 mM imidazole as
running and washing buffer, respectively, and with 300 mM imidazole for the elution
buffer [14].
For TrxA-His6 partner removal, the purified fusion protein was digested with TEV-
His6 protease overnight at 4 ◦C at the ratio of 1:20 (w/w) in running buffer. Elution buffer
was previously exchanged with running buffer using PD10 columns (GE Healthcare). The
cleaved frutalin was then purified from the fusion tags and protease through reverse purifi-
cation by incubation with 0.5 mL of HisPur™ Ni-NTA Resin (Thermo Fisher Scientific),
following manufacturer’s instructions as given for the batch purification method, using
the above-mentioned buffers, but in which the target protein (cFTL) was collected from the
resin washing steps.
Purified proteins were analyzed by SDS-PAGE using 15% (w/v) acrylamide gels,
followed by BlueSafe staining (NZYTech). Imidazole removal from proteins, and any other
buffer exchange, was performed using PD10 columns (GE Healthcare). The concentration
of the recombinant proteins was estimated from the absorbance at 280 nm using the
respective molar extinction coefficients. Recombinant proteins were maintained at 4 °C
until their use in subsequent in vitro studies.
4.3. Dynamic Light Scattering (DLS)
The size distribution of protein samples was determined with a Malvern Zetasizer,
MODEL NANO ZS (Malvern Instruments Limited, Worcestershire, UK). Protein in phos-
phate buffer (1 mL) at a concentration between 0.8–1.0 mg/mL was analyzed at room
temperature using a polystyrene cell. Ten measurements per sample were performed.
Protein samples were filtrated through 0.45 µm pore. Zetasizer software tool “MW & Shape
Estimates” (Worcestershire, UK) was used to determine expected hydrodynamic radius
using theoretical MW of proteins. The online ExPASy ProtParam tool was used to calculate
MW of proteins using primary amino acid sequences.
4.4. Hemagglutination Assays
Hemagglutinating studies were conducted as previously reported [8]. Briefly, lectins
were mixed 1:2 with a rabbit erythrocytes solution (2% (v/v) in 0.15 M NaCl) in the range
0.002–0.2 mg/mL in Eppendorfs, and incubated at 37 °C for 30 min, plus another 30 min at
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room temperature. Thereafter, samples were visually inspected for the presence or absence
of agglutination. Native frutalin, obtained as previously described [8], was included as
positive control. Three independent assays were performed.
4.5. Recombinant Frutalin Three-Dimensional (3D) Model Building
The fully automated protein homology-modelling server SWISS-MODEL [26] was
used to predict and evaluate the 3D model structure of recombinant frutalin. The X-ray
crystal structure of the frutalin from Artocarpus incisa (PDB ID: 4WOG) served as template.
Molecular illustrations were prepared using VMD [27].
4.6. Fluorescence Studies
Fluorescence studies were performed as previously described [8] using Spectrofluo-
rometer Horiba Aqualog 800 (Boeblingen, Germany). Gains in the intrinsic fluorescence
emission of recombinant frutalin in the presence of the non-fluorescent sugar methyl-α-
galactose (100 mM) were recorded at 328 nm. Data was analyzed using OriginPro 2015
software ((Boeblingen, Germany).
4.7. Human Cancer Cell Lines and Growth Conditions
Human colon adenocarcinoma HCT116 cell lines, expressing p53 (HCT116 p53+/+)
and respective p53 knockout (HCT116 p53−/−), were provided by B. Vogelstein (The Johns
Hopkins Kimmel Cancer Center, Baltimore, MD, USA); melanoma A375 cell line was
purchased from CLS Cell Lines Service GmbH (Eppelheim, Germany); human ovarian car-
cinoma IGROV-1 was provided by Professor Leonor David from Instituto de Investigação
e Inovação em Saúde, i3S (Porto, Portugal), human breast adenocarcinoma MDA-MB-231
and normal colon CCD-18Co cell lines were purchased from ATCC (Manassas, VA, USA).
Human cell lines used were routinely cultured in RPMI-1640 medium with UltraGlutamine
(Lonza, VWR), excepting CCD-18Co cells that were cultured in EMEM (Lonza, Ingrenor,
Porto, Portugal), supplemented with 10% fetal bovine serum (FBS; Gibco, Alfagene, Lis-
boa, Portugal), and maintained at 37 °C with 5% CO2. Cells were routinely tested for
mycoplasma infection using the MycoAlert™ PLUS mycoplasma detection kit (Lonza).
4.8. Sulforhodamine B (SRB) Assay
Human cell lines were seeded in 96-well plates at a density of 5.0 × 103 cells/well
(for p53+/+ and p53−/− HCT116, IGROV-1, MDA-MB-231, and CCD-18Co cells) and
4.5 × 103 cells/well (for A375 cells) for 24 h. Cells were treated with serial dilutions of
TrxFTL for additional 48 h. Recombinant frutalin from P. pastoris, obtained as previously
described [8], was included as positive control. Effects on cell proliferation were measured
by SRB assay, as previously described [28], and the concentration that induced half of
growth inhibition (GI50) was determined for each cell line using the GraphPad Prism
software version 7.0 (La Jolla, CA, USA).
Since the effects of TrxFTL and cFTL on cancer cells were identical, this study was
conducted with TrxFTL, to avoid extra purification steps of recombinant frutalin.
4.9. Statistical Analysis
Statistical significance was calculated for each data set based on at least three in-
dependent experiments. Data were analyzed using GraphPad Prism software v7.0 (San
Diego, CA, USA) and are presented as means± SEM. Unpaired Student’s t-test (two-tailed)
was applied to each dataset in order to compare average values; p < 0.05 was considered
statistically significant.
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